<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00707135</url>
  </required_header>
  <id_info>
    <org_study_id>13142A</org_study_id>
    <nct_id>NCT00707135</nct_id>
  </id_info>
  <brief_title>Rapamycin in Advanced Cancers</brief_title>
  <official_title>A Phase Ib Study of Rapamycin (Sirolimus) in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine the rapamycin dose equivalent to the recommended phase&#xD;
      II/III dose of temsirolimus and determine the observed toxicities and anti-tumor response of&#xD;
      rapamycin in patients with advanced cancers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose level equivalent to recommended phase 2/3 dose of temsirolimus</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>observed toxicities</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>anti-tumor effect</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <description>Rapamycin given once weekly in escalating doses. Higher dose levels will be split with the half the dose given on day 1 and half the dose on day 2 (24 hours later).</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rapamune</other_name>
    <other_name>sirolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignancy that is metastatic or unresectable and for which&#xD;
             standard curative or palliative measures do not exist or are no longer effective.&#xD;
&#xD;
          -  Patients with hematologic malignancies (lymphoma and CLL only) are eligible to&#xD;
             participate in the phase Ib portion of the trial only. Patients must have relapsed or&#xD;
             refractory disease that is no longer amenable to standard available therapy.&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy or radiation therapy&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  ECOG performance status less than or equal to 2&#xD;
&#xD;
          -  Life expectancy of greater than 3 months.&#xD;
&#xD;
          -  Normal organ and marrow function as defined below:&#xD;
&#xD;
               -  No transfusions of packed red blood cells with 1 week of starting treatment. An&#xD;
                  absolute level of hemoglobin does not constitute an eligibility criterion but&#xD;
                  patients should be transfused as clinically indicated.&#xD;
&#xD;
               -  Leukocytes ≥ 3,000/μL&#xD;
&#xD;
               -  WBC ≥ 1,500/μL for patients with hematologic malignancies&#xD;
&#xD;
               -  ANC ≥ 1,500/μL (≥1,000/μL for patients with hematologic malignancies)&#xD;
&#xD;
               -  Absolute lymphocyte count ≥ 1000/µL&#xD;
&#xD;
               -  CD4 count ≥ 500/μL&#xD;
&#xD;
               -  Platelets ≥ 100,000/μL (≥50,000/μL for patients with hematologic malignancies)&#xD;
&#xD;
               -  Total bilirubin within normal institutional limits&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) ≤ 2.5 times institutional upper limit of normal&#xD;
&#xD;
               -  Serum triglycerides ≤ 500 mg/dl&#xD;
&#xD;
               -  Creatinine within normal institutional limits OR&#xD;
&#xD;
               -  Creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels&#xD;
                  above institutional normal.&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C)&#xD;
             prior to entering the study. Not recovered from adverse events due to agents&#xD;
             administered more than 4 weeks earlier.&#xD;
&#xD;
          -  May not be receiving any other investigational agents.&#xD;
&#xD;
          -  Uncontrolled brain metastases or malignancy. Patients with brain metastases or a&#xD;
             malignant primary brain tumor must have stable neurologic status following local&#xD;
             therapy (surgery or radiation) for at least 8 weeks from definitive therapy, and must&#xD;
             be without neurologic dysfunction that would confound the evaluation of neurologic and&#xD;
             other adverse events. Patients cannot be receiving enzyme inducing anti-convulsants.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to rapamycin.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, history of interstitial lung disease (including pneumonitis, bronchiolitis&#xD;
             obliterans with organizing pneumonia, or pulmonary fibrosis) or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements.&#xD;
&#xD;
          -  Patients with severe immunodeficient states (as judged by the treating physician.&#xD;
&#xD;
          -  Pregnant women, breast-feeding must be stopped&#xD;
&#xD;
          -  HIV-positive patients are excluded due to possible pharmacokinetic interactions with&#xD;
             rapamycin.&#xD;
&#xD;
          -  Concurrent use of ketoconazole, cyclosporine, tacrolimus, and rifampin with rapamycin&#xD;
             is not permissible. Concurrent use of rapamycin with diltiazem is allowed but should&#xD;
             be done with caution or avoided.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>June 26, 2008</study_first_submitted>
  <study_first_submitted_qc>June 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2008</study_first_posted>
  <last_update_submitted>January 16, 2014</last_update_submitted>
  <last_update_submitted_qc>January 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

